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Noncoding RNAs are a feature of many herpesvirus genomes. They include microRNAs, whose function is the
subject of intense investigation, in addition to longer RNA molecules such as the Epstein-Barr virus-encoded
RNAs and herpesvirus saimiri U RNAs, which have been known for some time but whose function is still not
well defined. Murine gammaherpesvirus 68 (MHV-68) encodes eight viral tRNA-like molecules (vtRNAs) of
unknown function. Investigating the kinetics of expression of the vtRNAs, we observed that they were present
directly after infection with the virus. This strongly suggested that vtRNAs were part of the virion structure,
which was confirmed by their detection within various purified, RNase-treated preparations. Although both
viral and cellular mRNAs were also detected within the MHV-68 virion, the major RNA species present were
small RNAs of around 70 nucleotides in length. Interestingly, incorporation of viral mRNA was not related to
the relative abundance in infected cells, as M11 mRNA, which is present at low abundance, was found in
virions. MHV-76, which lacks the genes encoding the vtRNAs, also incorporated small RNA molecules within
the virion, suggesting a requirement for these molecules for virion maturation. In productively infected cells
the vtRNAs localized predominantly within the cytoplasm, although they also exhibited a globular pattern of
nuclear staining. Their presence in the cytoplasm is consistent with interaction with virion components prior
to maturation of virus particles. The significance of these findings for virion architecture and function is
discussed.
Noncoding RNA molecules have been recognized as a fea-
ture of the genomes of members of the herpesvirus family for
many years (1, 17, 28). They have been identified in numerous
viruses including the human gammaherpesviruses Epstein-
Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus
(KSHV) and are commonly expressed during latent infection.
The noncoding RNAs are expressed at high levels, suggesting
that they have important roles in virus pathogenesis, but de-
spite considerable interest, their function(s) is not well defined.
The most intensely studied herpesvirus noncoding RNAs are
the EBV-encoded RNAs (EBERs). These are RNA polymer-
ase (RNA pol) III transcripts present in both lytic and latent
infections which appear to have multiple functions including
resistance to apoptosis and control of the immune response as
well as a potential role in tumorigenesis (1, 7, 19, 23, 34). They
have been detected in both the nucleus and the cytoplasm of
infected cells (25). Herpesvirus saimiri also encodes a family of
small noncoding RNAs, the small nuclear Sm binding RNAs
herpesvirus saimiri U RNAs (HSUR) 1 to 7, which are ex-
pressed in transformed cells (14, 17). In contrast to the
EBERs, these are transcribed from RNA pol II promoters and
accumulate in the nucleus. A role for these RNAs in mRNA
stability has been proposed (18), and there is evidence that two
of these RNAs, HSUR 1 and 2, regulate transcription of genes
involved in T-cell activation (8). The polyadenylated nuclear
RNA (PAN RNA) encoded by KSHV is also an RNA pol II
transcript present in the nucleus but is expressed only during
lytic infection (29, 35). PAN RNA is the most abundant viral
RNA species in the nucleus of productively infected cells. Its
function is unknown, but a role in splicing has been suggested
(35).
Murine gammaherpesvirus 68 (MHV-68 or HV68; also
called MuHV-4) is widely used as a mouse model for the study
of replication and pathogenesis of the gammaherpesviruses.
Like EBV, MHV-68 encodes a set of RNA pol III-driven
noncoding RNAs. These eight transcripts, which encode
tRNA-like molecules capable of forming a cloverleaf second-
ary structure, are located in the left end of the genome, a
region known to be involved in pathogenesis (3). The viral
tRNA-like molecules (vtRNAs) each contain RNA pol III
promoter elements and are transcribed monocistronically. In-
terestingly, the primary transcripts are processed to produce
both the vtRNAs and a set of microRNA molecules (20). At
least four of the vtRNAs are not aminoacylated by cellular
aminoacyl-tRNA synthetases, and they are therefore not
thought to function as classical tRNAs during protein synthe-
sis. However, they are recognized and processed as tRNAs to
some extent by the host cell, with the addition of 3 CCA
termini (3). The vtRNAs are expressed to high levels during
both lytic and latent infection, and it is therefore likely that
they play a role during both infectious events, although no
function has been demonstrated so far.
Herpesvirus lytic replication involves the temporally regu-
lated expression of three sets of genes, with the immediate-
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early genes expressed first, then the early genes, and finally,
following viral DNA replication, the late genes. Expression of
the vtRNAs has been previously classified as immediate-early
(11), and yet their exact timing of expression has not been
investigated. The initial objective of this study was therefore to
characterize the expression pattern of the vtRNAs during lytic
infection. However, a preliminary investigation suggested that
the vtRNAs were present within the viral stock used and hence
either contaminated the stock or formed part of the virus
particle. Consequently, we investigated whether the vtRNAs
were packaged within the virus particle and hence were an
integral component of the infectious virion.
MATERIALS AND METHODS
Cell lines. The murine epithelial cell line C127 (ATCC CRL1616) was main-
tained in Dulbecco’s modified Eagle’s medium supplemented with 10% (vol/vol)
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin (Merck BDH), and 100
U/ml streptomycin (Merck BDH) (DME10). Baby hamster kidney fibroblast
cells (BHK-21) were maintained in Glasgow’s modified Eagle’s medium, supple-
mented with 10% (vol/vol) tryptose phosphate broth, 10% (vol/vol) newborn calf
serum, 2 mM L-glutamine (VWR, United Kingdom), 100 U/ml penicillin, and
100 U/ml streptomycin. Immortalized murine embryonic fibroblasts derived from
type I interferon (IFN) receptor-deficient mouse embryos by stable transfection
with the simian virus 40 T antigen ( SV1) were maintained in DME10.
Preparation of purified virus stocks. Murid herpesvirus 4 strain MHV-68
clone g2.4 (30) and MHV-76 (15) cell-associated virus stocks were prepared by
infection of BHK-21 cells at a multiplicity of infection (MOI) of 0.001 PFU/cell
as previously described (31). Supernatant virus was prepared by infection of 
SV1 at an MOI of 0.001 PFU/cell. Following complete cytopathic effect, the cell
suspension was centrifuged at 2,000  g for 20 min. The resulting supernatant
was centrifuged at 20,000  g for 2 h at 4°C in order to pellet the virus.
Virus stocks were purified by layering onto a 20% sucrose cushion and spun at
141,000 g for 1 h 20 min at 4°C. The pellet was resuspended in 1 ml RNase One
buffer (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH
7.9) for treatment with RNase One (New England Biolabs) or phosphate-buff-
ered saline (PBS) for further purification. For purification through a discontin-
uous sucrose gradient, the viral stock was applied onto 55%, 30%, and 10%
sucrose layered in descending order and banded by ultracentrifugation at 141,000
 g for 18 h at 4°C, following which a viral band was clearly visible. The band was
removed, sterile PBS was added to a total volume of 20 ml, and the purified virus
was concentrated by ultracentrifugation at 141,000  g for 1 h 20 min and
resuspended in 1 ml RNase One buffer. Purified virus stocks were treated with
700 units RNase One for 5 h at 37°C.
RT-PCR. RNA was extracted using RNAwiz (Ambion) according to the man-
ufacturer’s instructions, and the RNA was resuspended in 30 l RNase-free
water. Contaminating DNA was removed using DNA free (Ambion) according
to the manufacturer’s instructions. For the removal of DNA from purified viri-
ons, two DNase treatments were carried out, with an incubation at 95°C for 3 min
in between. Random priming reverse transcription was carried out using Super-
script II (Invitrogen) according to the manufacturer’s instructions. PCR was
carried out using the previously described primers to the vtRNAs, M3, M11,
DNA polymerase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
-actin (10, 11, 24). PCR mixtures contained between 1.5 and 5 mM MgCl2; 100
M each of dATP, dCTP, dGTP, and dTTP; 50 pmol of each primer; PCR buffer
(20 mM Tris [pH 8.4], 50 mM KCl); and 5 U Taq DNA polymerase (Invitrogen).
Reverse transcriptase PCR (RT-PCR) products were separated by agarose gel
electrophoresis.
Total RNA labeling. RNA isolated from virions was radiolabeled with 32P-
cytidine–3,5-bisphosphate (pCp) using T4 RNA ligase (New England Biolabs).
RNA was incubated with T4 reaction buffer (50 mM Tris-HCl, 10 mM MgCl2, 1
mM ATP, 10 mM dithiothreitol, pH 7.8), 10% (vol/vol) dimethyl sulfoxide, 20 U
SUPERase-In RNase inhibitor (Ambion), 250 Ci [32P]pCp, and 20 units T4
RNA ligase for 30 min at 37°C. Unincorporated nucleotides were removed with
Micro-Bio-Spin chromatography columns. The samples were fractionated on
either a 1% (wt/vol) agarose gel containing 6.7% (vol/vol) formaldehyde in 1
morpholinepropanesulfonic acid (MOPS) buffer or a Novex Tris-buffered EDTA
(TBE)–urea–10% polyacrylamide gel (Invitrogen). All gels were fixed in 10%
acetic acid-20% methanol for 20 min, and agarose gels were dried for 2 h at 80°C.
For detection of the radiolabeled RNA, the gels were exposed to Hyperfilm ECL
(GE Healthcare).
Northern blot analysis. For detection of vtRNA1, RNA was run on a Novex
TBE-urea-10% polyacrylamide gel (Invitrogen) and electrophoretically trans-
ferred to a Zetaprobe membrane (Bio-Rad) at 200 mA for 1 h in 0.25 TBE,
using a semidry blotter (Amcos), and the RNA was UV cross-linked to the
membrane. Labeled vtRNA1 probe was produced by incorporation of [32P]CTP
using the mirVana microRNA probe construction kit (Ambion, United King-
dom) using a synthetic oligonucleotide, 5-GCCAGAGTAGCTCAATTGGTC
CTGTCT-3. Hybridization was carried out in Ultrahyb (Ambion) according to
the manufacturer’s directions.
In situ hybridization. In situ hybridization was carried out using digoxigenin-
labeled antisense probes derived from pEH1.4 (a gift from S. Efstathiou) (3),
using a digoxigenin RNA labeling kit (Roche). Cytospins were prepared from
C127 cells infected with MHV-68 or MHV-76 at an MOI of 5 PFU/cell, for 24 h.
Cells were permeabilized in 0.5% Triton X-100 in PBS and rinsed in PBS and 2
SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate). Labeled probe (200
ng/ml) was diluted in hybridization buffer [50% (vol/vol) formamide, 5 salts
(0.05 M EDTA, 0.05 M PIPES [piperazine-N,N-bis(2-ethanesulfonic acid)], 0.6
M NaCl, pH 6.8), 0.1 sodium dodecyl sulfate, 5 Denhardt’s solution, 0.25
mg/ml salmon sperm DNA, 0.25 mg/ml yeast tRNA, 20 U/ml heparin, and 5
mg/ml dextran sulfate] and heated to 95°C for 2 min. Dithiothreitol was added to
10 mM. Hybridization was carried out at 55°C overnight. Unbound probe was
removed by washing with 2 SSC and 1 SSC at 37°C and 0.2 SSC at 55°C.
Indirect fluorescence detection of the digoxigenin-labeled probe was carried out
using a primary antidigoxigenin antibody (Roche), a secondary biotinylated an-
tibody (Vector Labs), and streptavidin-Alexa Fluor 488 (Invitrogen). The slides
were mounted in Vectashield mounting medium for fluorescence with propidium
iodide (Vector Labs).
RESULTS
Incorporation of the vtRNAs within MHV-68 cell lysate
stocks. To determine the exact timing of expression of the
vtRNAs, C127 cells were infected with virus stocks prepared
from lysates of MHV-68-infected BHK cells. RT-PCR carried
out on the extracted RNA indicated the presence of vtRNA1
from 30 min to 24 h postinfection (hpi) (Fig. 1A). The presence
of the vtRNA as early as 30 min following addition of the
virions was surprising. Although it was possible that viral gene
expression could have taken place by this time, it was perhaps
more likely that the vtRNAs were present within the virus
preparation. In order to investigate whether this was the case,
RNA was extracted from both the cell lysate MHV-68 stock
and infected cells at 0 hpi and was found to contain vtRNA1 by
RT-PCR (Fig. 1B). Given that the virus stock used for the
infection was produced from a crude cellular lysate of infected
BHK-21 cells, it was possible that the vtRNAs could have been
FIG. 1. (A) Expression of vtRNA1 in C127 cells infected with
MHV-68. C127 cells were infected at an MOI of 5 PFU/cell, and at
various times, the RNA was harvested and subjected to RT-PCR for
vtRNA1. Experiments were carried out in the presence (RT) or
absence (RT) of reverse transcriptase. (B) RNA was isolated from
the virus stock and from infected cells at 0 hpi and subjected to
RT-PCR for vtRNA1.
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present in the stock. However, as human cytomegalovirus
(HCMV), herpes simplex virus type 1 (HSV-1), and KSHV
virions have all been found to incorporate RNA (2, 4, 26), it
was possible that the vtRNAs were packaged within the
MHV-68 virion.
The BHK lysate-derived virions were purified by ultracen-
trifugation on a 20% sucrose cushion and treated with RNase
One to remove any remaining contaminating RNA from the
outside of the virus particles. The virions were then disrupted,
and the RNA was extracted. RT-PCR demonstrated the pres-
ence of vtRNA1 within the virus preparation (Fig. 2A). Fol-
lowing treatment of the extracted RNA with RNase One, no
PCR product was visible, demonstrating the ability of the en-
zyme to digest vtRNA1. In addition, PCR amplification was
not a result of contaminating genomic DNA, as no PCR prod-
uct was present when the reverse transcriptase was absent from
the reaction. PCRs were also carried out on the cDNA for the
remaining vtRNAs, which were all found to be present (Fig.
2B). In addition to the vtRNAs, both viral (M3) and cellular
(GAPDH and -actin) mRNAs could be found within the
sucrose cushion-purified virus stock.
The cell lysate virus stock was further purified through a 5 to
55% sucrose gradient, and the obvious, opaque virus band
(designated the virus band) was harvested. The band immedi-
ately above the virus band (the upper band) and the lower
band, which included the pellet, were also collected, and all
three were concentrated by ultracentrifugation. Following
RNase treatment, the virions were disrupted and the RNA was
extracted. RT-PCR demonstrated the presence of vtRNA1 in
all three preparations (Fig. 2C). However, no viral or cellular
mRNA transcripts, such as M3 or -actin, could be detected in
any of the bands by RT-PCR. Although the sucrose gradient-
purified virus stock appeared to be cleaner than that purified
through a sucrose cushion, as judged by the removal of the
mRNA molecules, electron micrographs of the virus prepara-
tions revealed that they still contained cellular debris (data not
shown). In addition, a 2-log decrease in virus titer following
ultracentrifugation through the sucrose gradient resulted in a
lower RNA yield, and hence, it is not clear whether the
mRNAs could not be detected due to their levels falling below
the limit of detection or as a result of further purification of the
virus stock.
vtRNAs are present within a highly purified supernatant
virus stock. To determine if the vtRNAs were present within
virions released into the cellular supernatant, MHV-68 was
grown within type I IFN receptor-deficient murine embryonic
fibroblasts, which produce high levels of extracellular virus (J.
Stewart, personal communication). This allowed for a much
easier purification of the viral stock, as contaminating cytoplas-
mic material was absent. The preparation was purified by ul-
tracentrifugation through a 20% sucrose cushion, resulting in a
high-titer (	1010 PFU/ml) virus stock. Transmission electron
microscopy of the resulting virus stock indicated that it con-
tained high levels of enveloped virions and relatively little
contaminating debris (data not shown). RT-PCR demon-
strated the presence of vtRNA1 within the RNase One-treated
supernatant virus stock (Table 1).
MHV-76 is a deletion mutant of MHV-68 which lacks four
genes found within the left end of the genome (M1 to M4)
along with the eight vtRNAs and nine microRNAs. MHV-76
produces yields of virus similar to and exhibits growth kinetics
identical to those of MHV-68 in vitro but is attenuated in vivo
(15). The incorporation of RNA molecules within MHV-76
virions was analyzed alongside that in MHV-68 virions in order
to investigate RNA packaging in the absence of the vtRNAs. In
FIG. 2. vtRNAs are present in purified MHV-68 virions. (A and B)
Cell-associated MHV-68 virions were purified through a sucrose cush-
ion, and RNA was extracted and subjected to RT-PCR. (A) RNA was
subjected to RT-PCR for vtRNA1 or treated with RNase One fol-
lowed by RT-PCR, showing that the vtRNA1 product was derived
from RNA. (B) RT-PCR of virion RNA showing the presence of
vtRNA2 to -8 and mRNAs for -actin, GAPDH, and M3 in virion
preparations. (C) RT-PCR on RNA extracted from MHV-68 grown in
BHK-21 cells and purified through a sucrose gradient. RT-PCR was
carried out for vtRNA1 and -actin on virus taken from the upper
band, lower band, and virus band. Experiments were carried out in the
presence () and absence () of reverse transcriptase. Positive (ve)
and negative (ve) controls were included in the reactions.
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addition, a mock preparation was produced following the same
protocol. To determine the specific RNA species present
within MHV-68 and MHV-76 viral particles, RT-PCR was
carried out on the RNA extracted from the extracellular viri-
ons. PCRs were carried out on the cDNA using primers spe-
cific for all eight vtRNAs and cellular (GAPDH and -actin)
and viral mRNA molecules. M3 and ORF65 mRNAs are
present at high levels at the late times of infection when the
virus particles are maturing. M11 and DNA polymerase
(ORF9), although expressed, are present at much lower levels
(11). The results of the PCR are summarized in Table 1. All
the vtRNAs were found to be present within the MHV-68 viral
preparation, except for vtRNA7, which, despite numerous as-
says, was never detected. As predicted, none of the vtRNAs
were present within either an MHV-76 or a mock-infected
preparation. The viral mRNA M3 could be detected within
MHV-68, but once again not in MHV-76, which is as expected
given that it lacks the M3 gene. Additional viral mRNAs could
be detected within both MHV-68 and MHV-76, including
ORF65, and surprisingly, given their apparent low level of
expression, M11 and DNA polymerase mRNAs were also
found to be packaged. The detection of cellular mRNAs within
the viral stocks appeared to vary, with both GAPDH and
-actin being present within the MHV-68 preparation. How-
ever, GAPDH mRNA could not be detected by RT-PCR
within the MHV-76 preparation. No cellular RNA molecules
could be detected by RT-PCR within the mock-infected prep-
aration. Hence, it appears that the presence of RNA molecules
within the virus preparations was due to their protection within
the virion and not a result of contamination from cellular
RNA.
Small RNA molecules are the major RNA species packaged
within the MHV-68 virion. Given that both MHV-68 and
MHV-76 package an assortment of RNA species, the nature of
the RNA present was determined by total RNA labeling using
radiolabeled ribonucleotides. Despite the presence of mRNA
molecules within the MHV-68 virion, as determined by RT-
PCR, the only RNAs detected using T4 labeling of RNA ex-
tracted from supernatant virus were around 100 nucleotides in
length (Fig. 3A). No other RNA species could be detected
using this method, indicating that both MHV-76 and MHV-68
preferentially package small RNA molecules. The absence of
any RNA species in the mock-infected preparation indicates
protection of the RNA within the virions and not contamina-
tion from cellular RNA molecules.
To determine the exact size of the RNA species present, the
experiment was repeated but this time the labeled RNA was
run on a 10% polyacrylamide-urea gel. The major RNA spe-
cies extracted from both MHV-68 and MHV-76 viral prepara-
tions were approximately 70 nucleotides in length (Fig. 3B),
indicating that in the absence of the vtRNAs (i.e., in MHV-76)
the virus is able to package RNA molecules of the same size.
Once again, no labeled RNA could be detected within the
mock-infected preparation.
To investigate whether the small polynucleotides present
within MHV-68 represent the vtRNAs, Northern blot analysis
was carried out. RNA was extracted from both MHV-76 and
MHV-68. Hybridization was carried out using an in vitro-tran-
scribed [32P]CTP-labeled probe specific for the first 20 nucle-
otides of vtRNA1. Two RNA species of approximately 70 and
90 nucleotides in length were detected within MHV-68 virions
(Fig. 3C). No hybridization to MHV-76 RNA was detected.
The 70-nucleotide fragment corresponds to fully processed
vtRNA. It is possible that the 90-nucleotide fragment repre-
sents RNA that has been semiprocessed from the longer pri-
mary transcript.
The vtRNAs localize mainly to the cytoplasm during lytic
infection. To investigate the subcellular localization of the
vtRNAs in greater detail, in situ hybridization was carried out
on C127 cells infected with MHV-68 for 24 h (Fig. 4). High
levels of vtRNAs could be detected within the cytoplasm,
where they exhibited a diffuse pattern of staining. In addition
the vtRNAs could be found to localize to specific areas within
the nucleus. The exclusion of host chromatin, based on the
propidium iodide staining (27), from areas of vtRNA staining
FIG. 3. Analysis of the RNA species present within purified virus
stocks. MHV-68 and MHV-76 were grown in mouse embryonic fibro-
blast cells lacking the type I IFN receptor and purified from cell-free
supernatants by centrifugation though a sucrose cushion. Virions were
treated with RNAse One prior to extraction of RNA. RNA was labeled
with [32P]CTP and fractionated on a 3% agarose gel (A), a 10%
polyacrylamide-urea gel together with a mock preparation (B), and a
Northern blot of purified virion RNAs probed with [32P]CTP-labeled
RNA probe specific for the first 20 nucleotides of vtRNA1 (C). Num-
bers at left of each panel are molecular sizes in nucleotides.
TABLE 1. RNA species present in purified MHV-68 and MHV-76
virions and in a mock preparation
RNA species
Presence in virion preparation
MHV-68 MHV-76 Mock
vtRNA1   
vtRNA2   
vtRNA3   
vtRNA4   
vtRNA5   
vtRNA6   
vtRNA7   
M3   
ORF65   
M11   
DNA polymerase   
-Actin   
GAPDH   
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suggests their localization to viral replication compartments
where herpesvirus DNA replication, transcription, and DNA
encapsidation take place (5, 9, 13, 21, 22). However, the lack of
a specific antibody to viral proteins found within replication
compartments compounded the difficulty of the assignment of
these structures. Treatment of the slides with RNase resulted
in loss of the signal, indicating specific binding to the vtRNAs
and not viral DNA.
DISCUSSION
In this study, we demonstrate that the vtRNAs are packaged
within the MHV-68 virion particle, as determined by their
presence within different viral preparations produced from
both cell-associated and extracellular virions. Extensive treat-
ment of the virions with a nuclease to digest RNA exterior to
the virus particles prior to RNA isolation makes it unlikely that
the results are due to contaminating RNA. It was possible that
homogenization of infected cells resulted in the production of
membranous vesicles which may also contain vtRNAs; how-
ever, the presence of the vtRNAs within extracellular virions
which did not contain homogenized cellular material argues
against this. We also demonstrate that, within infected cells,
the vtRNAs localize to both the nucleus and the cytoplasm,
although at least at late times in infection they were found at
higher levels within the cytoplasm.
Selective packaging of vtRNAs. Although mRNA molecules
were detected within the MHV-68 particle, the vtRNAs were
present with a greater abundance, as they were the only RNA
species detected by RT-PCR analysis on lower-titer sucrose
gradient-purified viral stocks. In addition, direct labeling of the
total RNA present within the virion indicated that the major
encapsidated RNA species are small RNA molecules of ap-
proximately 70 nucleotides in length.
Cellular and viral mRNAs have previously been found to be
packaged within the HCMV and HSV virions (4, 12, 26). In
addition a recent study by Bechtel et al. demonstrated that
along with 10 viral mRNA molecules, the noncoding PAN
RNA is encapsidated by KSHV (2). However, here we dem-
onstrated that, at least in the case of MHV-68, small RNAs are
selectively packaged within the virion. Interestingly, a deletion
mutant of MHV-68 which lacks the vtRNAs (MHV-76) also
appears to encapsidate small RNA molecules of the same size.
Given that the most abundant RNA species within cells of
approximately 70 nucleotides in length are tRNAs, it is likely
that the encapsidated RNA species within MHV-76 are cellu-
lar tRNAs. It is worth noting that we were unable to detect
vtRNA7 within purified virions. vtRNA7 is the only vtRNA
that contains a predicted intron and is thought to fold into only
a presplicing tRNA but not fully mature tRNA (3), further
supporting the preferential packaging of mature tRNAs within
the virion. All previous studies of RNA packaging by herpes-
viruses were based on the detection of specific transcripts by
RT-PCR, Northern blotting, and microarray analysis but not
the total RNA present, and hence, it is not clear whether the
high level of encapsidation of small RNA is unique to
MHV-68.
Mechanism of RNA packaging. A matter of controversy is
the mechanism by which RNA is incorporated within herpes-
virus particles. In the case of HCMV, it has been demonstrated
that viral and cellular RNAs are packaged in proportion to the
relative quantities present within infected cells at the time of
virion assembly (32). However, viral mRNA packaging by
HSV-1 and KSHV does not correspond to mRNA expression
levels within infected cells. A superficial analysis of the RNA
species present indicates that the very highly expressed
vtRNAs are the most abundant viral RNA within the virion.
However, the M11 transcript is one of the least abundantly
expressed genes within infected cells (11), and yet this was also
present within the virion. Therefore, this study suggests that
for MHV-68, the viral RNA is not packaged within the virion
in proportion to the expression level within the cell. An alter-
native theory is that RNA is selectively packaged, perhaps
through binding to viral proteins, in a way analogous to that of
genomic RNA packaging by RNA viruses. The seven vtRNAs
that are packaged are 75% homologous at the sequence level
as well as shared predicted structure. It is possible that they are
recognized via sequence as well as structural elements. Virion
proteins that are capable of binding packaged RNA have been
identified in both HSV-1 and HCMV (26, 32).
Functions of packaged RNA. A key issue arising from this
study is the possible function of encapsidated RNA and in
particular the vtRNAs. It has been shown elsewhere that a
number of virion mRNAs delivered into the cell are translated
(2). However, given that the vtRNAs do not encode protein,
they are not delivered into the host cell to allow immediate
translation. It is possible that, whatever role the vtRNAs play
during infection, it is beneficial for the virus to deliver the
vtRNAs immediately upon infection of the host cell. This does
not explain the apparent encapsidation of small RNA mole-
cules by MHV-76, although it is possible that in the absence of
the vtRNAs the virus still maintains the mechanism responsi-
ble for vtRNA packaging and cellular tRNAs are incorporated
in their place, effectively by mistake.
A further hypothesis is that the packaged RNA has a struc-
tural role, acting either as a scaffold during virion assembly or
as a form of molecular packaging maintaining the integrity of
the virion. tRNAs of both viral and cellular origin have been
proposed to act as nucleating agents during the assembly of the
plant virus brome mosaic virus (6). In retroviruses, RNA is
important for virion assembly (16, 33) and has also been found
FIG. 4. In situ hybridization for vtRNA1 to -4. C127 cells were
infected at an MOI of 5 PFU/cell for 24 h and probed with a digoxi-
genin-labeled RNA probe specific for vtRNA1 to -4. Detection of the
digoxigenin-labeled probe was carried out using biotinylated anti-
digoxigenin and streptavidin-Alexa Fluor 488. Sections were counter-
stained with propidium iodide (PI) and imaged using a Leica TCS-NT
confocal microscope. Treatment with RNase was also carried out prior
to hybridization.
VOL. 83, 2009 RNA PACKAGING BY MHV-68 2325
to be an integral part of the structure of retrovirus particles
(16). If RNA, and in particular low-molecular-weight RNA, is
important in virion assembly and structure, this would explain
the incorporation of cellular tRNAs within the MHV-76 virion.
It is of relevance that MHV-76 is not attenuated in exponen-
tially growing tissue culture cells but is severely attenuated
within the lymphoid system in vivo, where cellular tRNAs
levels may be more limited (15).
In conclusion, we have demonstrated the encapsidation of
small RNA molecules within the virion of MHV-68. The pres-
ence of these molecules argues for a specific interaction with
virion components and a function in early events in virus in-
fection. Further work is under way to determine whether the
vtRNAs interact with specific viral proteins and to identify
their role in virus pathogenesis.
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